<?xml version="1.0"?>
<Articles JournalTitle="Iranian Journal of Public Health">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Iranian Journal of Public Health</JournalTitle>
      <Issn>2251-6085</Issn>
      <Volume>34</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2005</Year>
        <Month>03</Month>
        <Day>15</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">High Prevalence of Parvovirus B19 IgG Antibody among Hemophilia Patients in Center for Special Diseases, Shiraz, Iran</title>
    <FirstPage>51</FirstPage>
    <LastPage>54</LastPage>
    <AuthorList>
      <Author>
        <FirstName></FirstName>
        <LastName>M Mahmoodian Shooshtari</LastName>
        <affiliation locale="en_US"></affiliation>
      </Author>
      <Author>
        <FirstName></FirstName>
        <LastName>M Nabi Foroghi</LastName>
        <affiliation locale="en_US"></affiliation>
      </Author>
      <Author>
        <FirstName></FirstName>
        <LastName>R Hamkar</LastName>
        <affiliation locale="en_US"></affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2015</Year>
        <Month>10</Month>
        <Day>03</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Human parvovirus B19, the causative agent of fifth disease in childhood, is non-enveloped DNA virus and resistant to many physicochemical agents.   B19 is a potential risk to hemophiliac patients receiving blood products. To determine the prevalence of the corresponding antibody in patients with hemophilia A or B or Von Will brand&#x2019;s disease (VWBD), we tested 180 hemophilia patients aged 1-45 years for anti B19 IgG.  This work was descriptive, cross-sectional study. The results were compared with those of 400 age-matched controls, male blood donors and male children (18-45 and 3-17 years of age, respectively). The overall prevalence of B19 IgG in the hemophilia patients was 74% (133/180), and in the controls 56.5% (226/400, P</abstract>
    <web_url>https://ijph.tums.ac.ir/index.php/ijph/article/view/1880</web_url>
    <pdf_url>https://ijph.tums.ac.ir/index.php/ijph/article/download/1880/1861</pdf_url>
  </Article>
</Articles>
